Physician profile
Amanda Watts
NPI 1205196110
$8,897.44
in general payments reported to CMS, 2019-2025
43 companies · $1,700 in 2025
The $1,700 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $790 · 2021: $1,225 · 2022: $1,620 · 2023: $1,806 · 2024: $1,322 · 2025: $1,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,828.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,683.06 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $800.03 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $644.53 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals Lp | $631.72 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $517.94 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $465.59 | 2019-2023 | Belsomra, Steglatro, Verquvo |
| Takeda Pharmaceuticals U.S.A., INC. | $433.93 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $425.46 | 2022-2025 | |
| Glaxosmithkline, LLC. | $368.31 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $333.98 | 2021-2025 | Trulance, Xifaxan |
| Pfizer INC. | $239.73 | 2019-2025 | |
| Abbott Laboratories | $210.14 | 2022-2025 | Freestyle Libre 3 |
| Lundbeck LLC | $193.61 | 2025 | Rexulti, Vyepti |
| Kowa Pharmaceuticals America, INC. | $192.94 | 2019-2025 | Zoryve |
| Sumitomo Pharma America, INC. | $189.24 | 2023-2025 | Gemtesa |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.